网络荟萃分析 6 种中成药联合米非司酮治疗子宫肌瘤的疗效：系统评价和网络荟萃分析方案。

Network meta-analysis of 6 kinds of Chinese patent medicines combined with mifepristone in the treatment of uterine fibroids: A protocol for systematic review and network meta-analysis.

机构信息

College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.

College of Rehabilitation Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.

出版信息

Medicine (Baltimore). 2021 Oct 22;100(42):e27523. doi: 10.1097/MD.0000000000027523.

DOI:10.1097/MD.0000000000027523

PMID:34678886

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8542145/

Abstract

BACKGROUND

Uterine fibroids are benign. They belong to the category of "abdominal mass" in traditional Chinese medicine, and pathogenesis is mainly caused by weakness of the body, qi stagnation, and blood stasis. Drug therapy is the preferred treatment of uterine fibroids in clinical practice, and mifepristone is the most commonly used drug. In the past decade, a large number of clinical randomized controlled trials have proven that Chinese patent medicine combined with mifepristone in the treatment of uterine fibroids has a better curative effect, fewer adverse reactions, and higher safety than mifepristone alone. However, there is a lack of evidence-based research. This study aims to integrate clinical data through network meta-analysis to provide more evidence-based medical evidence for clinical medication.

METHODS

The comprehensive search included Chinese and other-language databases, such as MEDLINE (PubMed), Web of Science, The Cochrane Library, China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform, China Scientific Journal Database, and China Biomedical Literature Database. Clinical randomized controlled trials of 6 Chinese patent medicines combined with mifepristone for the treatment of uterine fibroids, including Guizhi Fuling Capsule, Gongliuxiao Capsule, Gongliuqing Capsule, Danbie Capsule, Gongliuning Capsule, and Xiaojiean Capsule were retrieved. The search period was from January 2010 to April 2021. Two researchers screened the literature through EndNote and used Excel to extract data. RevMan 5.3 was used to evaluate the quality of the literature. Treatment measures were analyzed in R language, and a forest map and probability ranking map of various interventions were drawn. The network evidence map and correction comparison funnel map of various interventions were drawn by STATA 14.0 software.

RESULTS

This study provides the clinical efficacy and safety of network meta-analysis of 6 kinds of Chinese patent medicines combined with mifepristone in the treatment of uterine fibroids will be systematically evaluated or descriptively analyzed.

CONCLUSION

This study's purpose is to provide a reference for the clinical treatment of uterine fibroids to choose more effective intervention therapies.

摘要

背景

子宫肌瘤是良性的。它们属于中医“癥瘕”范畴，其发病机制主要是由于身体虚弱、气滞血瘀。药物治疗是临床治疗子宫肌瘤的首选方法，米非司酮是最常用的药物。在过去十年中，大量的临床随机对照试验已经证明，与单独使用米非司酮相比，中药联合米非司酮治疗子宫肌瘤具有更好的疗效、更少的不良反应和更高的安全性。然而，缺乏基于证据的研究。本研究旨在通过网络荟萃分析整合临床数据，为临床用药提供更多循证医学证据。

方法

全面检索包括 MEDLINE（PubMed）、Web of Science、The Cochrane Library、中国知网、万方数据知识服务平台、中国科学期刊数据库和中国生物医学文献数据库在内的中文和其他语言数据库，检索关于 6 种中药（桂枝茯苓胶囊、功劳消胶囊、宫瘤清胶囊、丹鳖胶囊、宫瘤宁胶囊和消结安胶囊）联合米非司酮治疗子宫肌瘤的临床随机对照试验。检索时间为 2010 年 1 月至 2021 年 4 月。两名研究人员通过 EndNote 筛选文献，并使用 Excel 提取数据。RevMan 5.3 用于评估文献质量。使用 R 语言分析治疗措施，并绘制各种干预措施的森林图和概率排序图。通过 STATA 14.0 软件绘制各种干预措施的网络证据图和校正比较漏斗图。